CANCER GENETICS AND GENOMICS LABORATORY HEREDITARY CANCER MULTI-GENE PANEL

BC CAN CER

BC CANCER

DEPT. OF PATHOLOGY AND LABORATORY MEDICINE FAX: 604-877-6294
ROOM 3307 - 600 WEST 10TH AVENUE MON-FRI 8:30AM-4
VANCOUVER BC V5Z-4E6 www.cancergenetic

604-877-6000 EXT 67-2094
FAX: 604-877-6294
MON-FRI 8:30AM-4:30PM
WWW.CANCERGENETICSLAB.CA
GENETIC.COUNSELLOR@BCCANCER.BC.CA

CANCER GENETICS LAB SHIRE LABEL USE ONLY

PATIENT INFORMATION									REQUESTING PHYSICIAN NOTE: SIGNATURE REQUIRED (BELOW)			
Last Name First an				nd Middle Names				ľ	Name			MSC
Date of Birth (dd/mmm/yyyy) Gender Male				Female Non Binary/Other/Not Disclosed				1	Phone	hone Fax		
PHN	Cerner MRN				,	Address						
Email Address									Email Address			
CONSENT									COPY PHYSICIANS (ALL INFORMATION IS NECESSARY)			
Your sample may be sent to a laboratory in the USA for testing. Your personal information (name, date of birth, sex, cancer history) would be sent with the sample. Please contact <u>genetic.counsellor@bccancer.bc.ca</u> if you have any questions or concerns.									Name MSC Address			
Patient agrees to their results being shared with relatives referred to BC Cancer for genetic testing Yes No												
If patient is unable to receive their results, it should be disclosed to (or shared with):									Name MSC			
Name	patient Contact Phone / Email				,	Address						
SPECIMEN									INTERPRETER			
Specimen Type Peripheral Blo	Store and ship at r delivery to Cancer (address above). D	aboratory	Colle	Collection Date (dd/mmm/yyyy)		-	Interpreter required? No Yes, Language:					
HEREDITARY CANCER TESTING INFORMATION												
 If your cancer is hereditary, you will have an appointment with a genetic counsellor. Your test results may have implications for relatives. Your test results may be used to guide your cancer treatment and tell us about new cancer risks. Under the Canadian Genetic Non-Discrimination Act (GNDA), companies (including insurers) and employers cannot ask for your genetic test results or ask you to have genetic testing. Any unused samples may be stored at the BC Cancer Genetics & Genomics Laboratory and may be used to develop new clinical genetic tests in BC. 												·
TEST REQUESTED												
Hereditary Cancer Multi-Gene Panel Testing SQ HCAGPB If your patient requires expedited testing for treatment planning, please email genetic.counsellor@bccancer.bc.ca												
				ANCESTE	RAL BA	ACKGROUND — SEL	ECT ALL THA	AT APPLY	1			
Africa / Caribbean	Asia East South/Central	Europ	oe / UK	Indigeno (First Natio Metis, Inc	ons,	Jewish Ashkenazi Sephardic	Middle East		-	South / Central Oth		Other
										Specify	<i>t</i> :	
TESTING INDICATION(S) — SELECT ALL THAT APPLY												
HER2-negative breast cancer, eligible for adjuvant Olaparib Hereditary Breast and Ovarian Cancer Breast cancer ≤ age 50 2 primary breast cancers at any age Triple negative (ER-PR-HER2-) breast cancer Ovarian, fallopian tube or peritoneal cancer (non-mucinous epithelial; incl. STIC) Male breast cancer Prostate Cancer (INHERCAN) Metastatic prostate cancer				Pancreatic Cancer (PANC CA) Pancreatic ductal adenocarcinoma (PDAC) Does patient have a first degree relative with PDAC? Yes No Unknown Pancreatic neuroendocrine tumour Medullary Thyroid Cancer (MTC) Medullary thyroid cancer Paraganglioma (PGL) Paraganglioma (includes pheo) Renal Cancer (RENAL) ≤ age 47				** Approved by Hereditary Cancer Program ** Confirmation of pathogenic variant result (include relevant report(s) from tumour testing or clinical trial/research testing) **INDICATION/VARIANT DETAILS (REQUIRED FOR TEST TO PROCEED):				
PHYSICIAN SIGNATURE (REQUIRED) By signing below, I hereby acknowledge that I have informed the patient about the implications of hereditary testing. DATE												
LAB USE PB E	DTA Other	-					HCP USE	F	Progeny	Initia	als	Date

ONLY